Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Milella

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Leukemia|March 14, 2008
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemiaL S Steelman, S L Abrams, J Whelan, et al.
British Journal of Cancer|June 1, 2006
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trialsG Ferretti, E Bria, D Giannarelli, et al.
Hepatology International|March 20, 2015
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcomeA Andriulli, F Morisco, A M Ippolito, et al.
ESMO Open|October 29, 2021
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-upS P D'Angelo, S Bhatia, A S Brohl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh studyA Santoro, V Gebbia, T Pressiani, et al.
ESMO Open|June 29, 2024
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT studyA Avancini, D Giannarelli, A Borsati, et al.
Expert Review of Clinical Pharmacology|January 21, 2021
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trialA Mennitto, E Verzoni, F Cognetti, et al.
Cancer Chemotherapy and Pharmacology|December 15, 2015
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinomaS Cereda, M Milella, S Cordio, et al.
ESMO Open|January 10, 2021
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapyM Ganzinelli, H Linardou, M F Alvisi, et al.
Annals of Hematology|May 6, 2004
Targeted therapy of AML new conceptsM Andreeff, M Milella, B Z Carter, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Leukemia|March 14, 2008
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemiaL S Steelman, S L Abrams, J Whelan, et al.
British Journal of Cancer|June 1, 2006
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trialsG Ferretti, E Bria, D Giannarelli, et al.
Hepatology International|March 20, 2015
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcomeA Andriulli, F Morisco, A M Ippolito, et al.
ESMO Open|October 29, 2021
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-upS P D'Angelo, S Bhatia, A S Brohl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh studyA Santoro, V Gebbia, T Pressiani, et al.
ESMO Open|June 29, 2024
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT studyA Avancini, D Giannarelli, A Borsati, et al.
Expert Review of Clinical Pharmacology|January 21, 2021
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trialA Mennitto, E Verzoni, F Cognetti, et al.
Cancer Chemotherapy and Pharmacology|December 15, 2015
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinomaS Cereda, M Milella, S Cordio, et al.
ESMO Open|January 10, 2021
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapyM Ganzinelli, H Linardou, M F Alvisi, et al.
Annals of Hematology|May 6, 2004
Targeted therapy of AML new conceptsM Andreeff, M Milella, B Z Carter, et al.
Pageof 13